Monrol and FutureChem Announced a Clinical Supply Partnership
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) is delighted to announce that it has reached an agreement in principal with FutureChem based in Seoul, South Korea, a radiopharmaceutical company, for the clinical supply of radioisotope, Lu-177 n.c.a. (Lutetium-177 non-carrier-added), to support FutureChem’s Investigational New Drug IND-enabling Phase 2 clinical trial with Ludotadipep, 177Lu-FC705 to assess the efficacy and safety for repeated administration of the recommended Ludotadipep dose in patients with metastatic castration resistant prostate cancer (mCRPC). Clinical supply contract signed by two parties on 18th of Oct 2022 in Barcelona. A new supply contract between Monrol and FutureChem will be signed following the commercialization of the product in South Korea and US.
Monrol General Manager Aydın Küçük,added: “We are delighted to be working with FutureChem to have a clinical supply agreement to support clinical development program of an innovative radiopharmaceutical product Ludotadipep, 177Lu-FC705 to assess the efficacy and safety in patients with metastatic castration resistant prostate cancer (mCRPC). Collaboration with FutureChem is another example of we continue our mission to improve quality of life for cancer patients and transform patient care for the future.”
Dae Yoon Chi, Chief Executive Officer, FutureChem said: “FutureChem is thrilled to be partnering with Monrol, a company with a broad set of offerings to support our development programs and pipeline. We look forward to rolling out the supply of high-quality radioisotopes to our Phase 2a clinical trial patients in US soon. We have a future prospect to expand this partnership, supply of radioisotope, Lu-177 n.c.a. by Monrol for the commercialization of the Ludotadipep, 177Lu-FC705”.
ENDS
About Monrol
Monrol is one of the world’s largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today’s nimble, lean, virtual companies effectively taking new product concepts into clinical trials, demonstrating proof of concept and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 50 countries around the globe. To learn more, visit www.monrol.com and LinkedIn.
About FutureChem
Since its establishment in 1999, FutureChem has led the radiopharmaceuticals industry through research and development. FutureChem is the global forerunner in the production of radiopharmaceutical precursors and compounds, development of remarkable radiopharmaceuticals, and worldwide commercialization of new medicine.
FutureChem developed competitive technologies and innovative products with a mission to grow the company into a world-class radiopharmaceuticals enterprise, so to contribute a healthy and happy society, protecting the health of patients.
For more information, please visit www.futurechem.co.kr
About FC705 and 177Lu-FC705
2nd generation PSMA-targeted therapeutic radiopharmaceuticals. 177Lu-FC705 belongs to the 2nd generation of albumin binders introduced drugs. Its hydrophilicity is higher than that of other compounds, and has low nonspecific binding. 177Lu-FC705 will have constantly increasing uptake in prostate cancer due to the introduction of albumin binder while it will be rapidly excreted from normal organs. In this regard, 177Lu labeled 177Lu-FC705 can be expected to have high therapeutic effect and very low damage to normal organs. Currently, efficacy of 177Lu-FC705 is being clinically tested in Phase 2 in Korea and 1/2a in US.
About n.c.a. Lutetium-177
Lutetium-177 n.c.a is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a production process enables treatment options that have the potential to improve treatment outcomes for certain cancer patients today and more potential treatment options in future under clinical development. The unique properties of Lu-177 n.c.a. make it a theranostically desirable radioisotope for peptide receptor radionuclide therapy (PRRT) to treat certain cancers like Neuro Endocrine Tumors (NET) and Prostate cancer. N.c.a. Lutetium-177 DMF by Monrol listed by FDA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005260/en/
Contact information
For further information please contact:
Monrol
Aydın Küçük
General Manager
monrol@monrol.com
FutureChem
Dae Yoon Chi
CEO
daeyoon.chi@futurechem.co.kr
Media Enquiries
Alkim Aydın
Email: alkim.aydin@monrol.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement11.12.2023 07:00:00 CET | Press release
Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210383233/en/ The deal provides Ferring with exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration. The financial details of this deal are undisclosed. “This agreement is the latest in Ferring’s long term mission to maximise the therapeutic potential of the gut microbiome for the benefit of patients. PharmaBiome’s unique technology enables identification and manufacturing of defined consortium live microbiome biotherapeutics that could reverse microbiome dysbiosis linked to disease,” said Carl Bilbo, Senior Vice President, Micr
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease10.12.2023 23:00:00 CET | Press release
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced the full results from the pivotal Phase 2 AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with refractory chronic graft-versus-host disease (GVHD) who had received at least two prior lines of systemic therapy. These data are featured today in the Plenary Scientific Session (Abstract #1) at the 65th American Society of Hematology Annual Meeting 2023 (ASH 2023), held December 9-12, 2023, in San Diego and virtually. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210634247/en/ The results, which build on previously announced topline data, show that the trial met the primary endpoint across all cohorts receiving axatilimab, at doses of 0.3 mg/kg every two weeks, 1.0 mg/kg every two weeks and 3.0 mg/kg every four weeks. Patients who received axatilimab at 0.3 mg/kg every two weeks achieved the highest overall re
Revolutionizing Water Stewardship – The City of Dire Dawa and Nedamco Africa Unveil Cutting-Edge Water Management Platform Initiative at COP28 | December 9th 2023 | COP28UAE Press Center9.12.2023 10:00:00 CET | Press release
Today, at COP28 in the UAE, the city of Dire Dawa (Ethiopia) Water Supply and Sewerage Authority (DDWSSA) and Nedamco Africa together with its partners Microsoft, Deltares, Hulo.ai and Isle Utilities announced the launch of the “Nedamco Catchment-City-Waste Water Management” (CCW) project for the city of Dire Dawa. The CCW solution by Nedamco Africa and its partners Microsoft, Deltares and Hulo.ai is an integrated technology platform that directly addresses the critical challenges of water losses and inefficient management, prevalent in rapidly urbanizing regions like Dire Dawa. It embodies a holistic approach to water management by harnessing digital twin technology, AI/ML, and satellite imagery to deliver comprehensive monitoring of water infrastructures, detect leakages, and make climate impact predictions with the goal to provide more access to water, more water availability as well as improved water quality. With the deployment of the CCW platform Dire Dawa envisions a transformat
Newmont Announces Successful Early Tender Results for the Exchange Offers and Consent Solicitations9.12.2023 01:51:00 CET | Press release
Newmont Corporation (Newmont or the Company) announced today, in connection with the previously announced offers to exchange (each, an “Exchange Offer” and, collectively, the “Exchange Offers”) any and all outstanding notes (the “Existing Newcrest Notes”) issued by Newcrest Finance Pty Limited, a wholly owned subsidiary of Newmont (“Newcrest Finance” and, together with Newmont, the “Issuers”), for (1) up to $1.65 billion aggregate principal amount of new notes to be issued by the Issuers (the “New Newmont Notes”) and (2) cash, and related consent solicitations (each, a “Consent Solicitation” and, collectively, the “Consent Solicitations”) to adopt certain proposed amendments to each of the indentures governing the Existing Newcrest Notes (the “Existing Newcrest Indentures Amendments”), that the Issuers have received tenders with respect to the aggregate principal amounts of Existing Newcrest Notes set forth below, which constitute the requisite consents needed to adopt the Existing New
Board Named a Leader in Gartner® Magic Quadrant™ for Financial Planning Software8.12.2023 17:18:00 CET | Press release
Board, the global leader for Intelligent Planning Solutions, today announced that it has been named a Leader in the 2023 Gartner Magic Quadrant for Financial Planning Software. The evaluation was based on specific criteria that analyzed Board’s overall Completeness of Vision and Ability to Execute. “We are thrilled to be named a Leader for the second consecutive year. We believe this recognition is indicative of the incredible value and positive impact our Intelligent Planning Solutions bring to global businesses,” said Jeff Casale, CEO of Board. “In today’s uncertain markets, organizations need a trusted enterprise partner to help innovate and enhance their financial planning and analysis processes to plan smarter and succeed faster. Our solution integrates planning processes in a single platform, offering strategy, finance, and operations with real-time analysis and data sharing, to deliver a truly intelligent approach.” A Gartner Magic Quadrant is a culmination of research in a spec